Freedom to Heal Act of 2025 | ChamberLight

IN COMMITTEE· 119TH CONGRESS

House BillHR 6434Health

Freedom to Heal Act of 2025

INTRO DEC 4· LAST ACTION DEC 4

READING

5MIN

COSPONSORS

17BIPARTISAN

READER REACTIONS0 TOTAL

NO VOTES YET · BE THE FIRST

Introduced only

LEGISLATIVE PROGRESS

STEP 2 / 8

Introduced

In Committee

Reported

Passed House

Passed Senate

Conference

To President

Became Law

WHAT THE BILL DOES

AI-written

This bill matters because it addresses a gap in patient access to experimental treatments, specifically for drugs categorized as Schedule I controlled substances. Currently, the strict federal controls on Schedule I drugs can create legal and logistical hurdles, even when a patient qualifies under the "Right to Try" law. If this bill becomes law, it could expand options for patients facing life-threatening conditions, potentially offering them a chance at a treatment that is still under investigation but holds promise.

Without this bill, patients might continue to struggle to access these specific types of investigational drugs, even if a manufacturer is willing to provide them and their doctor believes it could help. The bill attempts to balance the desire for patient access with the need to prevent the misuse or 'diversion' of controlled substances, a concern that is particularly high for Schedule I drugs.

KEY PROVISIONS

4AI-extracted

PROVISION 01

Creates a special registration process for physicians to administer Schedule I eligible investigational drugs to eligible patients under the federal Right to Try law.

This establishes a specific legal pathway for doctors to use certain highly-controlled experimental drugs for very ill patients.

PROVISION 02

Requires physicians applying for this special registration to provide evidence of existing controlled substance licenses, manufacturer agreements, state law compliance, and storage plans.

These requirements are designed to ensure physician qualification, drug legitimacy, and safety controls against misuse.

PROVISION 03

Sets deadlines for the Attorney General to act on applications (45 days for initial, 30 days for supplemental drug requests) and to issue implementing rules (interim rule in 240 days, final rule within 2 years).

These timelines aim to ensure a prompt and efficient process for both physicians and federal agencies.

PROVISION 04

Allows a single physician registration to cover multiple treatment sites within the same city or county if under the same organizational control, provided the Attorney General is notified.

This simplifies administrative burden for physicians treating patients at different locations under one practice or institution.

SPONSORSHIP

1 + 17

COSPONSOR BREAKDOWNBIPARTISAN · 94%

DEM 9 REP 8 IND 0

ACTION TIMELINE

2 EVENTS

DEC 4

Introduced in House

INTROREFERRAL

DEC 4

Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

INTROREFERRAL

BILL INFO

TypeHouse Bill

NumberHR 6434

Congress119th

StatusIn Committee

IntroducedDec 4, 2025

Last actionDec 4, 2025

READER REACTIONS

OVERALL SENTIMENT

No reactions yet. Be the first to weigh in.

Discussion

Loading comments...

Call my reps

IN COMMITTEE· 119TH CONGRESS · JUDICIARY COMMITTEE · INTRODUCED DEC 4, 2025

House BillHR 6434Health

Freedom to Heal Act of 2025

INTRODUCED DEC 4, 2025· LAST ACTION DEC 4, 2025

PASSAGE CHANCES

—%

READING

5 min

COSPONSORS

COMPLEXITY

Moderate

Call my reps Congress.gov

LEGISLATIVE PROGRESS

STEP 2 OF 8

Introduced

In Committee

Reported

Passed House

Passed Senate

Conference

To President

Became Law

Introduced
In Committee
Reported
Passed House
Passed Senate
Conference
To President
Became Law

WHAT THE BILL DOES

AI-written

KEY PROVISIONS

AI-extracted

high

Creates a special registration process for physicians to administer Schedule I eligible investigational drugs to eligible patients under the federal Right to Try law.

This establishes a specific legal pathway for doctors to use certain highly-controlled experimental drugs for very ill patients.

med

Requires physicians applying for this special registration to provide evidence of existing controlled substance licenses, manufacturer agreements, state law compliance, and storage plans.

These requirements are designed to ensure physician qualification, drug legitimacy, and safety controls against misuse.

med

These timelines aim to ensure a prompt and efficient process for both physicians and federal agencies.

low

Allows a single physician registration to cover multiple treatment sites within the same city or county if under the same organizational control, provided the Attorney General is notified.

This simplifies administrative burden for physicians treating patients at different locations under one practice or institution.

DEADLINES & DATES

AI-extracted

An AI model extracted this from the bill’s official record and can make mistakes. Check the official text ↗ (opens in new tab)

Not later than 45 days after receiving an application.

Attorney General must register the applicant or serve an order to show cause for initial applications.

30 days after the date on which the physician submits the supplemental notification.

Supplemental notifications for additional drug amounts are deemed approved unless the Attorney General serves an order to show cause.

Not later than 240 days after the date of enactment of this subsection.

Attorney General must issue an interim final rule to implement this subsection.

Not later than 2 years after issuing an interim final rule.

Attorney General must issue a final rule to implement this subsection.

GLOSSARY

AI-written

Controlled Substances Act: A federal law that regulates the manufacture, importation, possession, use, and distribution of certain drugs and substances. It classifies substances into different 'schedules' based on their potential for abuse and accepted medical use.
Schedule I Drugs: A category of drugs under the Controlled Substances Act that are considered to have a high potential for abuse and no currently accepted medical use in treatment in the United States. Examples include heroin, LSD, and ecstasy, though some are being investigated for medical purposes.
Right to Try Law: A federal law that allows patients with life-threatening diseases who have exhausted approved treatment options to access certain investigational (experimental) drugs that have completed initial safety trials but are not yet fully approved by the Food and Drug Administration (FDA).
Investigational Drug: An experimental drug that has not yet been approved by the FDA for general use, but is being studied in clinical trials to determine its safety and effectiveness.
Diversion: The transfer of any legally prescribed controlled substance from the individual for whom it was prescribed to another person, or its use for illicit purposes.
Attorney General: The head of the U.S. Department of Justice and the chief law enforcement officer of the federal government, overseeing agencies like the Drug Enforcement Administration (DEA).

ACTION TIMELINE

2 EVENTS

DEC 4, 25

Introduced in House

INTROREFERRAL

DEC 4, 25

INTROREFERRAL

READER REACTIONS

0 COMMENTS

WHAT DO YOU THINK?

What do you think?

0 votes

Discussion

Loading comments...

MORE INFORMATION

Committee Referrals

Judiciary CommitteeReferred

Dec 4, 2025

house

Search

Freedom to Heal Act of 2025

LEGISLATIVE PROGRESS

WHAT THE BILL DOES

KEY PROVISIONS

SPONSORSHIP

ACTION TIMELINE

BILL INFO

READER REACTIONS

Discussion

Freedom to Heal Act of 2025

LEGISLATIVE PROGRESS

WHAT THE BILL DOES

KEY PROVISIONS

DEADLINES & DATES

GLOSSARY

ACTION TIMELINE

SPONSORS

READER REACTIONS

What do you think?

Discussion

MORE INFORMATION

Committee Referrals

Related Legislation